Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner

被引:36
|
作者
Viswanath, Pavithra [1 ]
Radoul, Marina [1 ]
Izquierdo-Garcia, Jose Luis [2 ,3 ]
Luchman, Hema Artee [4 ,5 ]
Cairncross, J. Gregory [6 ,7 ]
Pieper, Russell O. [8 ]
Phillips, Joanna J. [8 ]
Ronen, Sabrina M. [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 1700 4th St,Box 2532,Byers Hall,3rd Floor,Suite, San Francisco, CA 94143 USA
[2] CNIC, Madrid, Spain
[3] CIBER Enfermedades Resp CIBERES, Madrid, Spain
[4] Univ Calgary, Dept Cell Biol & Anat, Calgary, AB, Canada
[5] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[6] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[7] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada
[8] Univ Calif San Francisco, Helen Diller Res Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
IDH1; mutation; 2-Hydroxyglutarate; Metabolic reprogramming; Magnetic resonance spectroscopy; Phosphocholine; Phosphoethanolamine; Choline kinase; Ethanolamine kinase; HIF-1; alpha; Brain tumors; MAGNETIC-RESONANCE-SPECTROSCOPY; CHOLINE KINASE ALPHA; CANCER-CELLS; PHOSPHOLIPID-METABOLISM; R132H MUTATION; P-31; NMR; HYPOXIA; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE; DIFFERENTIATION;
D O I
10.1186/s40170-018-0178-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Magnetic resonance spectroscopy (MRS) studies have identified elevated levels of the phospholipid precursor phosphocholine (PC) and phosphoethanolamine (PE) as metabolic hallmarks of cancer. Unusually, however, PC and PE levels are reduced in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas that produce the oncometabolite 2-hydroxyglutarate (2-HG) relative to wild-type IDH1 (IDHwt) gliomas. The goal of this study was to determine the molecular mechanism underlying this unusual metabolic reprogramming in IDHmut gliomas. Methods: Steady-state PC and PE were quantified using P-31-MRS. To quantify de novo PC and PE synthesis, we used C-13-MRS and measured flux to C-13-PC and C-13-PE in cells incubated with [1,2-C-13]-choline and [1,2-C-13]-ethanolamine. The activities of choline kinase (CK) and ethanolamine kinase (EK), the enzymes responsible for PC and PE synthesis, were quantified using P-31-MR-based assays. To interrogate the role of 2-HG, we examined IDHwt cells incubated with 2-HG and, conversely, IDHmut cells treated with the IDHmut inhibitor AGI-5198. To examine the role of hypoxia-inducible factor 1-alpha (HIF-1 alpha), we silenced HIF-1 alpha using RNA interference. To confirm our findings in vivo and in the clinic, we studied IDHwt and IDHmut orthotopic tumor xenografts and glioma patient biopsies. Results: De novo synthesis of PC and PE was reduced in IDHmut cells relative to IDHwt. Concomitantly, CK activity and EK activity were reduced in IDHmut cells. Pharmacological manipulation of 2-HG levels established that 2-HG was responsible for reduced CK activity, EK activity, PC and PE. 2-HG has previously been reported to stabilize levels of HIF-1 alpha, a known regulator of CK activity. Silencing HIF-1 alpha in IDHmut cells restored CK activity, EK activity, PC and PE to IDHwt levels. Our findings were recapitulated in IDHmut orthotopic tumor xenografts and, most importantly, in IDHmut patient biopsies, validating our findings in vivo and in the clinic. Conclusions: This study identifies, to our knowledge for the first time, a direct role for 2-HG in the downregulation of CK and EK activity, and thereby, PC and PE synthesis in IDHmut gliomas. These results highlight the unusual reprogramming of phospholipid metabolism in IDHmut gliomas and have implications for the identification of MRS-detectable metabolic biomarkers associated with 2-HG status.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is an eomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
    Showalter, Megan Reed
    Hatakeyama, Jason
    Cajka, Tomas
    VanderVorst, Kacey
    Carraway, Kermit L., III
    Fiehn, Oliver
    ELIFE, 2017, 6
  • [42] IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
    Zou, Peng
    Xu, Haitao
    Chen, Pin
    Yan, Qing
    Zhao, Lin
    Zhao, Peng
    Gu, Aihua
    PLOS ONE, 2013, 8 (07):
  • [43] Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
    Cho, Uiju
    Yang, Seung Ho
    Yoo, Changyoung
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (06)
  • [44] Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
    Ma, Rui
    Yun, Cai-Hong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (04) : 2912 - 2917
  • [45] Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
    Fathi, Amir T.
    Sadrzadeh, Hossein
    Comander, Amy H.
    Higgins, Amichaela J.
    Bardia, Aditya
    Perry, Ashley
    Burke, Ameghan
    Silver, Regina
    Matulis, Christina R.
    Straley, Kimberly S.
    Yen, Katharine E.
    Agresta, Sam
    Kim, Hyeryun
    Schenkein, David P.
    Borger, Darrell R.
    ONCOLOGIST, 2014, 19 (06) : 602 - 607
  • [46] In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma
    Balaji, E. Vignesh
    Satarker, Sairaj
    Kumar, B. Harish
    Pandey, Samyak
    Birangal, Sumit Raosaheb
    Nayak, Usha Y.
    Pai, K. Sreedhara Ranganath
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (07) : 3764 - 3789
  • [47] Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status
    Ohno, Makoto
    Narita, Yoshitaka
    Miyakita, Yasuji
    Okita, Yoshiko
    Matsushita, Yuko
    Yoshida, Akihiko
    Fukushima, Shintaro
    Ichimura, Koichi
    Kayama, Takamasa
    Shibui, Soichiro
    BRAIN TUMOR PATHOLOGY, 2012, 29 (04) : 183 - 191
  • [48] Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas
    Ohno, Makoto
    Narita, Yoshitaka
    Miyakita, Yasuji
    Matsushita, Yuko
    Yoshida, Akihiko
    Fukushima, Shintaro
    Ichimura, Koichi
    Shibui, Soichiro
    BRAIN TUMOR PATHOLOGY, 2013, 30 (04) : 224 - 232
  • [49] Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging
    Lee, Seunghyun
    Choi, Seung Hong
    Ryoo, Inseon
    Yoon, Tae Jin
    Kim, Tae Min
    Lee, Se-Hoon
    Park, Chul-Kee
    Kim, Ji-Hoon
    Sohn, Chul-Ho
    Park, Sung-Hye
    Kim, Il Han
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (01) : 141 - 150
  • [50] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
    Christian Hartmann
    Jochen Meyer
    Jörg Balss
    David Capper
    Wolf Mueller
    Arne Christians
    Jörg Felsberg
    Marietta Wolter
    Christian Mawrin
    Wolfgang Wick
    Michael Weller
    Christel Herold-Mende
    Andreas Unterberg
    Judith W. M. Jeuken
    Peter Wesseling
    Guido Reifenberger
    Andreas von Deimling
    Acta Neuropathologica, 2009, 118 : 469 - 474